PHASE-II STUDY OF RDNA HUMAN ALPHA-2 INTERFERON IN MULTIPLE-MYELOMA

  • 1 January 1985
    • journal article
    • research article
    • Vol. 69  (5) , 495-498
Abstract
This is a reported of a phase II trial of r[ribosomal]DNA human alpha-2 interferon (IFN) (Schering-Plough 30500) in previously treated patients with multiple myeloma. Patients received 2 MU/m2 of IFN by s.c. injection 3 days per wk for 3 mo. Responding patients continued receiving the same dose, but those with stable disease received 10 MU/m2 3 times per wk. Eighteen patients were treated. Two partial responses were seen, 1 at the lower dose and 1 at the higher dose. The lower dose was well tolerated, but 3 of 6 patients who received 10 MU/m2 had to stop treatment because of subjective toxicity. Hematological toxicity was mild. At this dose and schedule, IFN has only minimal activity in previously treated patients.

This publication has 0 references indexed in Scilit: